Subcutaneous absorption and tissue distribution. Adalimumab is administered by subcutaneous injection and reaches peak serum concentrations in approximately five days, with an absolute bioavailability of roughly 64%. Its approximately 14-day elimination half-life reflects FcRn-mediated IgG recycling in endothelial cells, enabling every-other-week dosing. As an IgG1 antibody, it distributes predominantly to vascular and extracellular fluid compartments, with measurable penetration into inflamed synovial fluid, intestinal mucosa, and psoriatic skin lesions.

Primary target engagement. Adalimumab is a fully human IgG1 monoclonal antibody that neutralizes TNF-α by binding TNF-α and thereby obstructing productive TNF–TNF receptor engagement. The crystal structure of the TNF-α–adalimumab Fab complex at 3.1 Å resolution reveals that the antibody engages a discontinuous epitope across TNF-α protomers via both heavy- and light-chain CDRs, burying 2,540 Ų of surface area. Critically, this epitope directly overlaps the TNF receptor-binding site, and the structural data show that adalimumab prevents ligands from binding to TNFR2, blocking receptor engagement by steric occlusion. In addition to soluble TNF, adalimumab binds cell-surface transmembrane TNF-α, having been shown to be bound to transmembrane TNF-α on TNF-expressing cells, enabling blockade at the membrane level. The full-length IgG1 also forms higher-order multivalent assemblies with the TNF trimer; electron microscopy reveals complex structures consisting of 1:1, 1:2, 2:2, and 3:2 adalimumab–TNF complexes, which increase functional avidity and promote durable TNF sequestration at inflammatory sites.

Downstream NF-κB suppression and transcriptional reprogramming. By disrupting TNF–TNFR signaling, adalimumab suppresses TNF-driven NF-κB transcriptional output. In U937 NF-κB reporter assays, TNF stimulation led to a 122-fold increase in NF-κB luciferase activity that was reduced to baseline by adalimumab. Consistent with this pathway-level effect, adalimumab normalizes TNF-induced expression of NF-κB-responsive adhesion molecules, lowering ICAM-1 surface expression to baseline at 16.7 nM. At the gene and chromatin level, adalimumab reverses LPS-induced upregulation of NF-κB-associated genes including IKBKB, IRAK1, TRAF2, MAP3K7, and TNFAIP3 in keratinocytes, with concordant protein-level changes. It also reshapes inflammatory microRNA patterns: anti-inflammatory miRNAs including miR-125b and miR-30a are restored while pro-survival miRNAs are downregulated, supporting broader normalization of TNF-coupled regulatory networks.

Th17-axis suppression. TNF blockade converges on Th17-associated cytokine programs. In Th17-polarized cells from healthy subjects and patients with rheumatoid arthritis, adalimumab suppresses IL-17A, IL-17F, and IL-22 production, accompanied by decreased phospho-p38, phospho-p65, phospho-STAT3, and RORγt levels, with decreased histone H3/H4 acetylation at the RORγt promoter region.

Fc-mediated effector functions. As an IgG1 antibody, adalimumab engages Fcγ receptors and promotes antibody-dependent and complement-dependent cytotoxic mechanisms against membrane TNF-bearing cells, with biosimilar data confirming similar Fcγ receptor binding and equivalent ADCC and CDC effector functions. Adalimumab induces complement-dependent cytotoxicity in mTNF-transfected cells with activity comparable to infliximab; certolizumab pegol, which lacks an Fc region, does not mediate either CDC or ADCC, confirming the requirement for an intact IgG1 Fc. An F(ab')₂ fragment retains the ability to trigger redox-linked signaling that is independent of the Fc portion of adalimumab and involves NADPH oxidase activation, indicating that some downstream outcomes derive from ligation-induced tmTNF signaling rather than Fc-mediated cytotoxic recruitment alone.

Reverse signaling through transmembrane TNF. Engagement of membrane TNF-α propagates outside-to-inside reverse signaling that reshapes immune-cell survival and turnover. In tmTNF-expressing Jurkat T-cell systems, adalimumab induces apoptosis and cell-cycle arrest via outside-to-inside transduction through transmembrane TNF-α, while monocytic contexts show caspase-3 activation in a caspase-dependent apoptosis program.

Clinical translation. These molecular and cellular events align with observed therapeutic benefit. After sequential injections in rheumatoid arthritis, adalimumab drives a progressive restoration of iTNF-α-positive CD14+ monocyte frequencies toward healthy-donor levels after 12 injections, reflecting durable remodeling of TNF-axis immune biology. Loss of response in some patients reflects immunogenicity: neutralizing anti-adalimumab antibodies abolish TNF blockade and abolish the restoration of iTNF-α+ monocyte frequencies, directly linking molecular target engagement to the observed clinical outcome.